Literature DB >> 28092499

Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.

Anish Babu, Ranganayaki Muralidharan, Narsireddy Amreddy, Meghna Mehta, Anupama Munshi, Rajagopal Ramesh.   

Abstract

Gene silencing through RNA interference (RNAi) has emerged as a potential strategy in manipulating cancer causing genes by complementary base-pairing mechanism. Small interfering RNA (siRNA) is an important RNAi tool that has found significant application in cancer therapy. However due to lack of stability, poor cellular uptake and high probability of loss-of-function due to degradation, siRNA therapeutic strategies seek safe and efficient delivery vehicles for in vivo applications. The current review discusses various nanoparticle systems currently used for siRNA delivery for cancer therapy, with emphasis on liposome based gene delivery systems. The discussion also includes various methods availed to improve nanoparticle based-siRNA delivery with target specificity and superior efficiency. Further this review describes challenges and perspectives on the development of safe and efficient nanoparticle based-siRNA-delivery systems for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28092499      PMCID: PMC6198667          DOI: 10.1109/TNB.2016.2621730

Source DB:  PubMed          Journal:  IEEE Trans Nanobioscience        ISSN: 1536-1241            Impact factor:   2.935


  129 in total

Review 1.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

2.  Use of adeno-associated viral vector for delivery of small interfering RNA.

Authors:  Raghuvir S Tomar; Hittu Matta; Preet M Chaudhary
Journal:  Oncogene       Date:  2003-08-28       Impact factor: 9.867

Review 3.  Druggable signaling proteins.

Authors:  Mouldy Sioud; Marianne Leirdal
Journal:  Methods Mol Biol       Date:  2007

Review 4.  RNA interference and its role in cancer therapy.

Authors:  Behzad Mansoori; Siamak Sandoghchian Shotorbani; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2014-08-10

5.  A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor.

Authors:  Kathleen A Fitzgerald; Meenakshi Malhotra; Matt Gooding; Florence Sallas; James C Evans; Raphael Darcy; Caitriona M O'Driscoll
Journal:  Int J Pharm       Date:  2015-12-22       Impact factor: 5.875

6.  Quantum Dots in an Amphiphilic Polyethyleneimine Derivative Platform for Cellular Labeling, Targeting, Gene Delivery, and Ratiometric Oxygen Sensing.

Authors:  Joonhyuck Park; Junhwa Lee; Jungheon Kwag; Yeonggyeong Baek; Bumju Kim; Calvin Jinse Yoon; Seoyeon Bok; So-Hye Cho; Ki Hean Kim; G-One Ahn; Sungjee Kim
Journal:  ACS Nano       Date:  2015-06-09       Impact factor: 15.881

7.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

8.  PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells.

Authors:  Xiao-Xuan Liu; Palma Rocchi; Fan-Qi Qu; Shu-Quan Zheng; Zi-Cai Liang; Martin Gleave; Juan Iovanna; Ling Peng
Journal:  ChemMedChem       Date:  2009-08       Impact factor: 3.466

9.  Breaking up the correlation between efficacy and toxicity for nonviral gene delivery.

Authors:  Miriam Breunig; Uta Lungwitz; Renate Liebl; Achim Goepferich
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

10.  PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery.

Authors:  Yi Zhao; Wei Wang; Shutao Guo; Yuhua Wang; Lei Miao; Yang Xiong; Leaf Huang
Journal:  Nat Commun       Date:  2016-06-06       Impact factor: 14.919

View more
  9 in total

Review 1.  Nanoparticulate RNA delivery systems in cancer.

Authors:  Ankur Sharma; Niraj Kumar Jha; Kajal Dahiya; Vivek Kumar Singh; Kundan Chaurasiya; Aditya Narayan Jha; Saurabh Kumar Jha; Prabhu Chandra Mishra; Sunny Dholpuria; Rani Astya; Parma Nand; Amit Kumar; Janne Ruokolainen; Kavindra Kumar Kesari
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-30

2.  Non-covalent Encapsulation of siRNA with Cell-Penetrating Peptides.

Authors:  Martina Tuttolomondo; Henrik J Ditzel
Journal:  Methods Mol Biol       Date:  2021

3.  Cationic Dendrimers for siRNA Delivery: An Overview of Methods for In Vitro/In Vivo Characterization.

Authors:  Erik Laurini; Suzana Aulic; Domenico Marson; Maurizio Fermeglia; Sabrina Pricl
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Drug delivery approaches for HuR-targeted therapy for lung cancer.

Authors:  Rajeswari Raguraman; Santny Shanmugarama; Meghna Mehta; Jo Elle Peterson; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-11-22       Impact factor: 15.470

5.  Dual-function hybrid nanoparticles with gene silencing and anti-inflammatory effects.

Authors:  Oksana Fihurka; Vasyl Sava; Juan Sanchez-Ramos
Journal:  Nanomedicine (Lond)       Date:  2022-04-04       Impact factor: 6.096

6.  HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo.

Authors:  Felix Alonso-Valenteen; Sayuri Pacheco; Dustin Srinivas; Altan Rentsendorj; David Chu; Jay Lubow; Jessica Sims; Tianxin Miao; Simoun Mikhael; Jae Youn Hwang; Ravinder Abrol; Lali K Medina Kauwe
Journal:  Nucleic Acids Res       Date:  2019-12-02       Impact factor: 16.971

7.  Targeted delivery and enhanced gene-silencing activity of centrally modified folic acid-siRNA conjugates.

Authors:  Lidya Salim; Golam Islam; Jean-Paul Desaulniers
Journal:  Nucleic Acids Res       Date:  2020-01-10       Impact factor: 16.971

Review 8.  Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma.

Authors:  Mariam Mroweh; Thomas Decaens; Patrice N Marche; Zuzana Macek Jilkova; Flora Clément
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

9.  Hepatic stellate cells specific liposomes with the Toll-like receptor 4 shRNA attenuates liver fibrosis.

Authors:  Yuwei Zhang; Yang Li; Tong Mu; Nanwei Tong; Ping Cheng
Journal:  J Cell Mol Med       Date:  2020-12-18       Impact factor: 5.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.